Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18423672 | 0.83 | KDM4E (0.82) | KDM4ECYP1A2ALOX15LMNAKMT2A | |
| SCHEMBL12932615 | 0.81 | NR2E1 (0.67) | KDM4ECYP1A2LMNAKMT2AMEN1 | |
| SCHEMBL7400700 | 0.80 | ALOX15 (0.93) | KDM4ECYP1A2ALOX15LMNAKMT2A | |
| SCHEMBL768488 | 0.80 | ALOX15 (0.93) | KDM4ECYP1A2ALOX15LMNAKMT2A | |
| SCHEMBL768489 | 0.80 | ALOX15 (0.93) | KDM4ECYP1A2ALOX15LMNAKMT2A | |
| SCHEMBL13328786 | 0.79 | KDM4E (0.65) | KDM4ECYP1A2ALOX15LMNAKMT2A | |
| SCHEMBL6264190 | 0.79 | HIF1A (0.57) | KDM4ELMNAADRB2ADRB1ADRB3 | |
| Hydrochloric Acid SCHEMBL11100810 | 0.79 | ALOX15 (0.97) | KDM4ECYP1A2ALOX15LMNAKMT2A | |
| Mephenesin SCHEMBL6482337 | 0.78 | CYP1A2 (1.00) | KDM4ECYP1A2ALOX15LMNAKMT2A | |
| Mephenesin SCHEMBL332864 | 0.78 | CYP1A2 (1.00) | KDM4ECYP1A2ALOX15LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021760-A1 | CRYSTALLINE VAP-1 AND USES THEREOF | SALMINEN TIINA | 2011-01-27 | — | — | US | disclosed |
| US-20110021760-A1 | CRYSTALLINE VAP-1 AND USES THEREOF | SALMINEN TIINA | 2011-01-27 | — | — | US | disclosed |
| US-7499847-B2 | Crystalline VAP-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2009-03-03 | — | — | US | disclosed |
| US-7499847-B2 | Crystalline VAP-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2009-03-03 | — | — | US | disclosed |
| US-20070093646-A1 | Crystalline vap-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2007-04-26 | — | — | US | disclosed |
| US-20070093646-A1 | Crystalline vap-1 and uses thereof | BIOTIE THERAPIES CORPORATION (FI) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093646-A1 | Crystalline vap-1 and uses thereof | VCAM1, VAPB, VAPA | KDM4E 4544/4885CYP1A2 4287/4885ALOX15 2589/4885 |
| US-20110021760-A1 | CRYSTALLINE VAP-1 AND USES THEREOF | VAPB, VCAM1, VAPA | KDM4E 4518/4885CYP1A2 4294/4885ALOX15 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.